Evidence map›Paper›PMID 27108361›Full record

ReviewCurrent cardiology reports2016

Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss.

Daniela Cardinale, Gina Biasillo, Carlo Maria Cipolla

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Daniela CardinaleCardioncology Unit, European Institute of Oncology, I.R.C.C.S., Via Ripamonti 435, 20141, Milan, Italy. daniela.cardinale@ieo.it.
Gina BiasilloCardiology Division, European Institute of Oncology, I.R.C.C.S., Milan, Italy.
Carlo Maria CipollaCardiology Division, European Institute of Oncology, I.R.C.C.S., Milan, Italy.
European Institute of Oncology · ITRipamonti · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in oncologic therapies have led to considerable improvements in prognosis and survival. However, these improvements may ultimately be diminished by the increase of cardiovascular side effects. Typically, both conventional and new antitumoral therapies may induce asymptomatic or symptomatic left ventricular dysfunction. Its development still remains a major deterrent that may compromise clinical effectiveness of cancer treatment, independently of the oncologic prognosis, having a serious impact on the patient's survival and quality of life. Hence, prevention of cardiotoxicity remains a crucial topic both for cardiologists and oncologists. Many strategies to mitigate the risk of cardiotoxicity have been developed, including cardiac function monitoring, limitation of chemotherapy doses, use of anthracycline analogues and cardioprotectants, and early detection of cardiotoxicity by biomarkers, followed by prophylactic intervention in selected high risk patients. We reviewed the currently available approaches which have been demonstrated to be effective in preventing or limiting cancer drug-induced cardiotoxicity.

Indexed as

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCardiotoxicityCardiotoxinsCardiovascular DiseasesHumansNeoplasmsPrognosisQuality of LifeVentricular Dysfunction, LeftAntineoplastic AgentsCardiotoxinsBiomarkersCancer therapyCardioncologyCardiotoxicityLeft ventricular dysfunctionPrevention

Identifiers

PMID27108361
OpenAlexW2337149546

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.